Inici
→
Consulteu per autor

Consulteu per autor "Clotet, Bonaventura"

Ara es mostren els elements 1-20 de 38

Pàgina següent

A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques

Mothe, B.; Hu, Xintao; Llano, Anuska; Rosati, Margherita; Olvera, Alex; Kulkarni, Viraj; Valentin, Antonio; Alicea, Candido; Pilkington, Guy R.; Sardesai, Niranjan J.; Rocafort, Muntsa; Crespo, Manel; Carrillo, Jorge; Marco, Andrés; Mullins, James I.; Dorrell, Lucy; Hanke, Thomas; Clotet, Bonaventura; Pavlakis, George N.; Felber, Barbara; Brander, Christian (BioMed Central, 2015)

Background: None of the HIV T-cell vaccine candidates that have reached advanced clinical testing have been able to induce protective T cell immunity. A major reason for these failures may have been suboptimal T cell immunogen ...
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients

Podzamczer Palter, Daniel; Imaz, A.; Pérez, I.; Viciana, P.; Valencia, E.; Curto, J.; Martín, T.; Castaño, M.; Rojas, J.; Espinosa, N.; Moreno, V.; Asensi, V.; Iribarren, José Antonio; Clotet, Bonaventura; Force, Lluis; Bachiller, P.; Knobel, Hernando; López Bernaldo de Quirós, Juan Carlos; Blanco, J.R.; Rozas N.; Vergas, J.; Ocampo, A.; Camacho, A.; Flores, J.; Gómez-Sirvent J.L. (Oxford University Press, 2014)

Objectives: To present clinical experience with a regimen including abacavir/lamivudine+darunavir/ritonavir in a cohort of HIV-1-infected patients. Methods: A retrospective, multicentre cohort study, including all ...
Alternative Effector-Function Profiling Identifies Broad HIV-Specific T-Cell Responses in Highly HIV-Exposed Individuals Who Remain Uninfected

Ruiz-Riol, Marta; Llano, Anuska; Ibarrondo, Javier; Zamarreño, Jennifer; Yusim, Karina; Back, Vanessa; Mothe, B.; Pérez-Alvarez, Susana; Fernández, M.A.; Requena, Gerard; Meulbroek, Michael; Pujol, Ferran; Leon, Agathe; Cobarsi, P.; Korber, Bette T.; Clotet, Bonaventura; Ganoza, C.; Sánchez, Jorge; Coll, J.; Brander, Christian (Oxford University Press, 2015)

The characterization of host immune responses to human immunodeficiency virus (HIV) in HIV controllers and individuals with high exposure but seronegativity to HIV (HESN) is needed to guide the development of effective ...
Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals

Molinos-Albert, Luis M.; Carrillo, Jorge; Curriu, Marta; Rodríguez de la Concepción, Maria L.; Marfil, Sílvia; García, Elisabet; Clotet, Bonaventura; Blanco, Julià (Biomed central, 2014)

Background The MPER region of the HIV-1 envelope glycoprotein gp41 is targeted by broadly neutralizing antibodies. However, the localization of this epitope in a hydrophobic environment seems to hamper the elicitation of ...
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression

Di Yacovo, María Silvana; Moltó, José; Ferrer, Elena; Curran, Adrian; Else, Laura; Gisslén, Magnus; Clotet, Bonaventura; Tiraboschi, Juan M.; Niubò, Jordi; Vila, Antonia; Zetterberg, H.; Back, David; Podzamczer Palter, Daniel (Oxford University Press, 2015)

Objectives: The objective of this study was to assess whether a lower dose than the currently used one of darunavir/ ritonavir might achieve good CSF concentrations and contribute to inhibition of CNS viral replication. Patients ...
Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients

Echeverria, Patricia; Guardiola, M.; González, Marta; Vallvé, Joan Carles; Bonjoch, Anna; Puig, Jordi; Clotet, Bonaventura; Ribalta, J.; Negredo, Eugenia (Elsevier, 2015)

Several studies have reported associations between lipid parameters and clinical progression of HIV infection. We performed a cross-sectional study including 468 antiretroviral-treated HIV-infected patients to investigate ...
Classification models for neurocognitive impairment in HIV infection based on demographic and clinical variables

Muñoz-Moreno, José A.; Pérez Alvarez, Núria; Muñoz-Murillo, A.; Prats, A.; Garolera, M.; Jurado, M.A.; Fumaz, C.R.; Negredo, Eugenia; Ferrer, M.J.; Clotet, Bonaventura (Plos One, 2014)

Objective: We used demographic and clinical data to design practical classification models for prediction of neurocognitive impairment (NCI) in people with HIV infection. Methods: The study population comprised 331 ...
Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years

Negredo, Eugenia; Bonjoch, Anna; Pérez Alvarez, Núria; Ornelas, Arelly; Puig, Jordi; Herrero, C.; Estany, Carla; Río, L. del; Gregorio, S. di; Echeverria, Patricia; Clotet, Bonaventura (Blackwell Publishing, 2015)

Objectives Given the need for easily managed treatment of osteoporosis in HIV-infected patients, we evaluated the efficacy and tolerability of two doses of zoledronate, by comparing three groups of patients: those with ...
Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man

Franco, S.; Tural, C.; Nevot, M.; Moltó, José; Rockstroh, J.K.; Clotet, Bonaventura; Martínez, M.A. (WB Saunders, 2014)

There is an international epidemic of hepatitis C virus (HCV) infection among human immunodeficiency virus–infected men who have sex with men. Transmission of HCV variants that are resistant to recently approved direct-acting ...
Determinants of virological failure and antiretroviral drug resistance in Mozambique

Rupérez, María; Pou, Christian; Maculuve, Sonia; Cedeño, Samandhy; Luis, Leopoldina; Rodríguez, Judith; Letang, Emilio; Moltó, José; Macete, Eusébio; Clotet, Bonaventura; Alonso, Pedro; Menéndez, Clara; Naniche, Denise; Paredes, Roger (Oxford University Press, 2015)

Objectives: The objective of this study was to inform public health actions to limit first-line ART failure and HIV drug resistance in Mozambique. Methods: This was a cross-sectional study. HIV-1-infected adults on ...
Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals

Massanella, Marta; Ouchi, Dan; Marfil, Sílvia; Llibre, Josep M.; Puertas, M.C.; Buzon, Maria J.; Richman, Douglas D.; Orna, Elisa; Stevenson, Mario; Gatell, J.M.; Domingo, Pere; Negredo, Eugenia; Martinez Picado, Francisco Javier; Clotet, Bonaventura; Blanco, Julià (Public Library of Science, 2014)

Abstract Background HIV-1 infection increases plasma levels of inflammatory markers. Combination antiretroviral therapy (cART) does not restore inflammatory markers to normal levels. Since intensification of cART ...
Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4R T cells of antiretroviral therapy suppressed patients

Puertas, M.C.; Salgado, Maria; Morón López, Sara; Ouchi, Dan; Muñoz-Moreno, José A.; Clotet, Bonaventura; Martinez Picado, Francisco Javier (Lippincott Williams & Wilkins, 2014)

Previous in-vitro data pointed out lithium, an activator of the b-catenin signalling pathway, as a modulator of HIV-1 transcription. We assessed the effect of in-vivo administration of lithium on viral latency modulation ...
Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals

Kawana-Tachikawa, A.; Llibre, Josep M.; Bravo, Isabel; Escrig, R.; Mothe, B.; Puig, Jordi; Puertas, M.C.; Martinez Picado, Francisco Javier; Blanco, Julià; Manzardo, C.; Miró, J.M.; Iwamoto, A.; Pozniak, A.L.; Gatell, J.M.; Clotet, Bonaventura; Brander, Christian (Public Library of Science, 2014)

Background The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. Methods Subjects recently infected with HIV-1 were randomized to receive anti-retroviral ...
Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029

Surdo, M.; Alteri, C.; Puertas, M.C.; Saccomandi, P.; Parrotta, L.; Swenson, L.; Chapman, D.; Costa, G.; Artese, A.; Balestra, E.; Aquaro, S.; Alcaro, S.; Lewis, M.; Clotet, Bonaventura; Harrigan, R.; Valdez, H.; Svicher, V.; Perno, C.F.; Martinez Picado, Francisco Javier; Ceccherini-Silberstein, Francesca (Wiley, 2015)

We characterized maraviroc susceptibility of dual/mixed tropic viruses from subjects enrolled onto phase IIb study A4001029. Maraviroc baseline plasma samples from 13 multidrugexperienced subjects were sequenced and the ...
Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia

Llibre, Josep M.; Bravo, Isabel; Ornelas, Arelly; Santos, José R.; Puig, Jordi; Martín Iguacel, Raquel; Paredes, Roger; Clotet, Bonaventura (Plos One, 2015)

Background Switching subjects with persistently undetectable HIV-1 viremia under antiretroviral treatment (ART) to once-daily tenofovir/emtricitabine (or lamivudine) + nevirapine is a cost-effective and well-tolerated ...
gp120/CD4 Blocking Antibodies Are Frequently Elicited in ART-naive Chronically HIV-1 Infected Individuals

Carrillo, Jorge; Molinos-Albert, Luis M.; Rodríguez de la Concepción, Maria L.; Marfil, Sílvia; García, Elisabet; Clotet, Bonaventura; Blanco, Julià (Mary Ann Liebert, Inc, 2014)
Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals

Carrillo, Jorge; Molinos-Albert, Luis M.; Rodríguez de la Concepción, Maria L.; Marfil, Sílvia; García, Elisabet; Derking, Ronald; Sanders, Rogier W.; Clotet, Bonaventura; Blanco, Julià (Plos One, 2015)

Antibodies with the ability to block the interaction of HIV-1 envelope glycoprotein (Env) gp120 with CD4, including those overlapping the CD4 binding site (CD4bs antibodies), can protect from infection by HIV-1, and their ...
Hidden costs of antiretroviral treatment: the public health efficiency of drug packaging

Andreu-Crespo, A.; Llibre, Josep M.; Cardona-Peitx, G.; Sala-Piñol, F.; Clotet, Bonaventura; Bonafont-Pujol, X. (Dove Medical Press, 2015)

While the overall percentage of unused antiretroviral medicines returned to the hospital pharmacy is low, their cost is quite high. Adverse events, treatment failure, pharmacokinetic interactions, pregnancy, or treatment ...
High Prevalence of Signs of Renal Damage Despite Normal Renal Function in a Cohort of HIV-Infected Patients: Evaluation of Associated Factors

Bonjoch, Anna; Juega, J.; Puig, Jordi; Pérez Alvarez, Núria; Aiestarán, A.; Echeverria, Patricia; Pérez, V.; Clotet, Bonaventura; Romero, R.; Bonet, J.; Negredo, Eugenia (Mary Ann Liebert, 2014)

Renal disorders are an emerging problem in HIV-infected patients. We performed a cross-sectional study of the first 1000 HIV-infected patients attended at our HIV unit who agreed to participate. We determined the frequency of ...
Improved Prediction of Salvage Antiretroviral Therapy Outcomes Using Ultrasensitive HIV-1 Drug Resistance Testing

Pou, Christian; Noguera-Julian, Marc; Pérez-Alvarez, Susana; Garcia, Federico; Delgado, Rafael; Dalmau, David; Álvarez-Tejado, Miguel; González, Dimitri; Chueca, Natalia; Sayada, Chalom; Pulido, Federico; Ibáñez, Laura; Rodríguez, Cristina; Casadellà, Maria; Santos, José R.; Ruiz, Lídia; Clotet, Bonaventura; Paredes, Roger (Oxford University Press, 2014)

Background. The clinical relevance of ultrasensitive human immunodeficiency virus type 1 (HIV-1) genotypic resistance testing in antiretroviral treatment (ART)-experienced individuals remains unknown. Methods. This was ...

Ara es mostren els elements 1-20 de 38

Pàgina següent

Buscar al RIUVic

Cerca avançada

Llistar per

Tot el repositori

Consulteu per autor "Clotet, Bonaventura"

Consulteu per autor "Clotet, Bonaventura"

Buscar al RIUVic

Llistar per

Tot el repositori